Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial

medRxiv(2021)10.1101/2021.03.31.21254494Source: DataRank Database

Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial is a research paper published in medRxiv (2021). On theSindex it has a DataRank of 4.6. It has been cited 59 times, with 54 citing works in its 1-hop citation network.

N/A

4.6DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access59 citations · 54 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04651790

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: greenTopics (23)IDs (PubMed, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 13%Citation Network 87%

Base Score Contribution

0.614

From this paper's citation signal

Citation Network Contribution

4.0

From 48 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 54 citers.

Reduced mortality rate after coronavac vaccine among healthcare workers
Journal of Infection202119 citations6 referencesContributes 0.499
Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
Human Vaccines & Immunotherapeutics202112 citations8 referencesContributes 0.321
Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers
Journal of Medical Virology202197 citations16 referencesContributes 0.287
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
The Lancet Infectious Diseases2021355 citations26 referencesContributes 0.226
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
The Lancet2021931 citations31 referencesContributes 0.221

Authors (46)

Katia Abarca ORCID,Pablo A. González ORCID,Nicolás M. S. Gálvez ORCID,Jorge A. Soto ORCID,Luisa F. Duarte ORCID

Live enrichment

PubMed:35441164 OpenAlex:https://openalex.org/W3143074411

green

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2021/04/01/2021.03.31.21254494.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2021.03.31.21254494

repositoryhttps://doi.org/10.1101/2021.03.31.21254494

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35441164

Fields of Study

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesDiverse Scientific Research Studies

Keywords

ImmunogenicityMedicineClinical trialInterim analysisPlaceboInterimAdverse effectPandemicHerd immunityInternal medicineImmunizationImmunologyPediatricsVaccinationCoronavirus disease 2019 (COVID-19)DiseaseAntibodyAlternative medicineInfectious disease (medical specialty)Pathology

Sustainable Development Goals

SDG 0: Good health and well-being